Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin G Sanda

Showing results (41-50 of 180) with videos related to

Pageof 18
Sort By:
Journal of the National Cancer Institute|May 8, 2003
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancerDaniel R Rhodes, Martin G Sanda, Arie P Otte, et al.
Radiology. Imaging Cancer|March 29, 2021
In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRIKareem K Elfatairy, Christopher P Filson, Martin G Sanda, et al.
Urology|July 13, 2004
Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counselingAtreya Dash, Rodney L Dunn, Jennifer Resh, et al.
Urology|July 26, 2002
Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on CancerAtreya Dash, Martin G Sanda, Menggang Yu, et al.
The Prostate|February 28, 2008
Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapyYilin C Neeley, Mohamed S Arredouani, Brent Hollenbeck, et al.
Urology|April 3, 2002
Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapyBrent K Hollenbeck, Rodney L Dunn, John T Wei, et al.
Oncology Nursing Forum|October 29, 2013
Survivorship after prostate cancer treatment: spouses' quality of life at 36 monthsJanet Harden, Martin G Sanda, John Thomas Wei, et al.
Urology|April 22, 2018
Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United StatesWen Liu, Dattatraya Patil, David H Howard, et al.
Cancer Nursing|June 26, 2012
Partners' long-term appraisal of their caregiving experience, marital satisfaction, sexual satisfaction, and quality of life 2 years after prostate cancer treatmentJanet K Harden, Martin G Sanda, John T Wei, et al.
Cancer Immunology, Immunotherapy : CII|February 13, 2008
Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancerStephanie S Tseng-Rogenski, Mohamed S Arredouani, Yilin C Neeley, et al.
Pageof 18

Showing results (41-50 of 180) with videos related to

Sort By:
Pageof 18
Journal of the National Cancer Institute|May 8, 2003
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancerDaniel R Rhodes, Martin G Sanda, Arie P Otte, et al.
Radiology. Imaging Cancer|March 29, 2021
In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRIKareem K Elfatairy, Christopher P Filson, Martin G Sanda, et al.
Urology|July 13, 2004
Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counselingAtreya Dash, Rodney L Dunn, Jennifer Resh, et al.
Urology|July 26, 2002
Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on CancerAtreya Dash, Martin G Sanda, Menggang Yu, et al.
The Prostate|February 28, 2008
Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapyYilin C Neeley, Mohamed S Arredouani, Brent Hollenbeck, et al.
Urology|April 3, 2002
Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapyBrent K Hollenbeck, Rodney L Dunn, John T Wei, et al.
Oncology Nursing Forum|October 29, 2013
Survivorship after prostate cancer treatment: spouses' quality of life at 36 monthsJanet Harden, Martin G Sanda, John Thomas Wei, et al.
Urology|April 22, 2018
Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United StatesWen Liu, Dattatraya Patil, David H Howard, et al.
Cancer Nursing|June 26, 2012
Partners' long-term appraisal of their caregiving experience, marital satisfaction, sexual satisfaction, and quality of life 2 years after prostate cancer treatmentJanet K Harden, Martin G Sanda, John T Wei, et al.
Cancer Immunology, Immunotherapy : CII|February 13, 2008
Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancerStephanie S Tseng-Rogenski, Mohamed S Arredouani, Yilin C Neeley, et al.
Pageof 18